Bexson Biomedical, Inc., a US-based biopharmaceutical company, announced on Tuesday that it has added Robert S Langer ScD to its Scientific Advisory Board (SAB).
Dr Langer serves as the David H. Koch Institute professor at MIT. He has served as both a member and chairman of the United States Food and Drug Administration's Science Board. He is the co-founder of Moderna.
Gregg Peterson, Bexson CEO, said, 'We are excited to have Dr Langer join our Scientific Advisory Board as a world leader in new biotechnology advancements and inventions who understands the complexities of the regulatory pathway for such advancements given his service as chairman of the FDA Science Board. Furthermore, we believe his addition to our SAB is a testament for our formulation technology, SEVALENT's, potential to disrupt the small molecule injectable market, bringing traditionally expensive, clinically delivered therapies, to the patients' home.'
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial